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The introduction of oral phosphodiesterase type 5 inhibitor therapy in 1998 revolutionized the treatment 
of erectile dysfunction. Erectile dysfunction is the most common sexual problem in men. It often has 
a profound effect on intimate relationships and quality of life. The analysis of pharmaceuticals is an 
important part of the drug development process as well as for routine analysis and quality control of 
commercial formulations. Whereas the determination of sildenafil citrate, vardenafil and tadalafil are 
well documented by a variety of methods, there are few publications about the determination of udenafil, 
lodenafil carbonate, mirodenafil and avanafil. The paper presents a brief review of the action mechanism, 
adverse effects, pharmacokinetics and the most recent analytical methods that can determine drug 
concentration in biological matrices and pharmaceutical formulations of these four drugs.
Uniterms: Phosphodiesterase type 5 inhibitors/determination/pharmaceutical preparations. 
Phosphodiesterase type 5 inhibitors/determination/biological samples. Analytical methods. Erectile 
dysfunction.
A introdução da terapia oral com inibidores da fosfodiesterase tipo 5, em 1998, revolucionou o tratamento 
da disfunção erétil. A disfunção erétil é o problema sexual mais comum em homens. Muitas vezes tem 
um efeito profundo nas relações íntimas e na qualidade de vida. A análise de produtos farmacêuticos é 
uma parte importante do processo de desenvolvimento de fármacos, bem como para a análise de rotina 
e controle de qualidade das formulações comerciais. Enquanto a determinação do citrato de sildenafila, 
vardenafila e tadalafila está bem documentada por uma variedade de métodos, existem poucas publicações 
sobre a determinação de udenafila, carbonato de lodenafila, mirodenafila e avanafila. O artigo apresenta 
uma breve revisão do mecanismo de ação, efeitos adversos, farmacocinética e os mais recentes métodos 
analíticos, que podem determinar a concentração do fármaco em matrizes biológicas e formulações 
farmacêuticas destes quatro fármacos.
Unitermos: Inibidores da fosfodiesterase tipo 5/determinação/preparações farmacêuticas. Inibidores da 
fosfodiesterase tipo 5/determinação/matrizes biológicas Métodos analíticos. Disfunção erétil.
INTRODUCTION
The National Institutes of Health (NIH) Consensus 
Development Conference on Impotence defined erectile 
dysfunction (ED) as the inability to achieve or maintain 
an erection sufficient for satisfactory sexual performance 
(NIH, 1993). The Massachusetts Male Aging Study 
(MMAS), the first large community-based observational 
survey of men aged 40 to 70 years, has demonstrated a 
combined prevalence of minimal, moderate and complete 
ED in 52% of men. The annual incidence rate (cases per 
1,000 man-years) increased with each decade of age and 
this rate was different for men 40-49 (12.4), 50-59 (29.8) 
and 60-69 (46.4) years old (Johannes et al., 2000). The 
projection for 2025 shows that approximately 322 million 
men will have ED, with the largest projected increases in 
the developing world, i.e., Africa, Asia, and South America 
(Ayatac et al., 1999). In Brazil, the overall incidence rate 
of ED was 65.6 cases per 1000 persons/year. The estimate 
for Brazilian men 40 to 69 years old was approximately 
C. F. Codevilla, T. S. Castilhos, A. M. Bergold2
1,025,600 new cases per year. The Brazilian estimate was 
greater than the MMAS study, maybe because the MMAS 
population was healthier than Brazilian study sample, 
like fewer smokers, fewer men with heart diseases and 
hypertension (Moreira et al., 2003).
Erectile dysfunction is often assumed to be a natural 
concomitant of the aging process, to be tolerated along 
with other conditions associated with aging. This as-
sumption may not be entirely correct (Nih, 1993). Other 
causes of ED were well described over the years, includ-
ing neurogenic, endocrinological and arteriogenic sources 
(Berookhim, Bar-Chama, 2011).
There are several disorders associated with ED, 
including hypertension, hyperlipidemia, testosterone 
deficiency/hypogonadism, diabetes, cardiovascular dis-
ease, obesity, lower urinary tract disorders associated 
with lower urinary tract symptoms (LUTS), depression, 
alcohol abuse, smoking, chronic obstructive pulmonary 
disease (Levine, 2000; Foresta et al., 2008; Singh et al., 
2009; Aversa et al., 2010; Berookhim, Bar-Chama 2011; 
Vignera et al., 2012). 
The most exciting change in the treatment options 
available for patients with ED are the oral therapies (Levine, 
2000). In 1998, a new class of drugs, the phosphodiesterase 
type 5 inhibitors (PDE5i) was introduced. PDE5i represent 
the first-line oral therapy for ED and the success of PDE5i 
therapy has dramatically changed the management of erec-
tile dysfunction over the past decade (Gratz et al., 2004; 
Eardley, 2006; Williams, Melman, 2012).
Sildenafil citrate (Viagra®) was the first drug ap-
proved for the treatment of ED in 1998. The United States 
Food and Drug Administration (FDA) approved tadalafil 
(Cialis®) and vardenafil hydrochloride (Levitra®) in 2003 
(Zou et al., 2006; De Orsi et al., 2009). Lodenafil carbon-
ate (Helleva®) is PDE5i developed in Brazil. It is a dimer 
that acts as a prodrug delivering lodenafil in vivo (Toque 
et al., 2008; Glina et al., 2009).
Recently, other PDE5i were developed. Udenafil 
(Zydena®) is also a potent and selective PDE5i developed 
by Dong-A Pharmaceutical Company in Korea (Kim et 
al., 2008; Han et al., 2010). It has not yet been approved 
by FDA or the European Medicines Agency (EMEA) and 
was only approved by the Korean Food and Drug Ad-
ministration (KFDA), being currently used in Korea and 
Russia (Alwaal et al., 2011; Cho et al., 2012). Mirodenafil 
(Mvix®), recently marketed in South Korea (Choi et al., 
2009), is reported to have an excellent profile of efficacy 
for erectile dysfunction (Lee et al., 2009; Kim et al., 
2010). One of the recently developed PDE5i, avanafil is a 
promising medication for ED due to its favorable pharma-
cokinetics, safety, and efficacy (Jung et al., 2010; Alwaal 
et al., 2011). FDA approved avanafil (Stendra®) in April 
27 (Traynor, 2012).
The first and most extensively investigated agent is 
sildenafil citrate (McNamara; Donatucci, 2011). There are 
several studies in the literature reporting the determination 
of sildenafil citrate in pharmaceuticals, plasma samples, 
herbal drugs or dietary supplements using liquid chroma-
tography (LC) methods (Eerkes et al., 2002; Sheu et al., 
2003; Wang et al., 2005; Reepmeyer, Woodruff, 2007; 
Reddy, Reddy, 2008; Ortiz et al., 2010; Bartošová et al., 
2011; Hasegawa et al., 2012), gas chromatography (GC) 
(Berzas et al., 2002; Kim et al., 2003a; Man et al., 2009; 
Strano-Rossi et al., 2010) and capillary electrophoresis 
(CE) (Qin, Li, 2002; Flores et al., 2004).
Likewise, vardenafil and tadalafil in different ma-
trices were analyzed using different analytical systems, 
such as LC (Gratz et al., 2004; Ramakrishna et al., 2004; 
Madhavi et al., 2008; Farthing et al., 2010; Lake et al., 
2010; Di et al., 2011; Lee et al., 2011; Hasegawa et al. 
2012), gas chromatography (Man et al., 2009; Papoutsis 
et al., 2010; Strano-Rossi et al., 2010) and capillary elec-
trophoresis (Ali, Aboul-Enein et al., 2004; Flores et al., 
2004; Idris; Alnajjar, 2007).
Accordingly, this review focuses on some cur-
rently available oral therapies for ED. A brief review of 
the phosphodiesterase type 5 inhibitors, mechanism of 
action, adverse effects, pharmacokinetics and analytical 
methodologies employed for the determination of four 
PDE5i (udenafil, lodenafil carbonate, mirodenafil and 
avanafil) is presented.
Physiology of erectile dysfunction and PDE5i 
mechanism of action 
Erections are initiated, maintained, and terminated 
because of a complex interaction between the neural and 
vascular components as well as the penile vasculature 
(McNamara, Donatucci, 2011). Visual, auditory, and 
tactile erectogenic stimuli are integrated and processed 
centrally in several hypothalamic structures. Once inte-
grated, both branches of the autonomic nervous system 
recruit nerves innervating the erectile tissues of the penis 
(Barret et al., 2005).
The main physiologic event is the release of nitric 
oxide (NO) from the autonomic nerve endings and the 
endothelial cells in the corpus cavernosum. Release of 
NO leads to relaxation of smooth muscle cells in the cor-
pora cavernosa vasculature and tumescence followed by 
passive veno-occlusion as the subtunical venule plexus is 
compressed against the rigid tunica albuginea. NO facili-
tates vasodilatation and relaxation by activating guanylate 
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cyclase (GC). GC then catalyzes the breakdown of guano-
sine triphosphate into 3’5’-cyclic guanosine monophos-
phate (cGMP), leading to smooth muscle relaxation in the 
blood vessels supplying the corpus cavernosum, resulting 
in increased blood flow and an erection (Williams, Mel-
man, 2012). Levels of cGMP in the smooth muscle cells of 
the penis are regulated by the enzyme phosphodiesterase 
type 5 (Barret et al., 2005; Albersen et al., 2011; McNa-
mara, Donatucci, 2011).
PDE5i are nonhydrolyzable analogs of cGMP and 
exert their beneficial effects on smooth muscle relaxation 
competitively binding to the catalytic site of PDE5 (Alber-
sen et al., 2011). PDE5i inhibit the degradation of cGMP 
by phosphodiesterase type 5, increasing blood flow to the 
penis during sexual stimulation (Gooren, 2008).
Adverse events with PDE5i
Adverse event profiles for all of the PDE5i are 
similar and are the result of the vasoactive nature of these 
agents, producing vasodilation in vascular beds other than 
the corpora cavernosa. The most common side effects re-
ported following the use of PDE5i include headache, flush-
ing, dyspepsia, nasal congestion (Carson, 2007; Albersen 
et al., 2011; McNamara, Donatucci, 2011). Adverse events 
are generally mild in nature and self-limited by continuous 
use, and the dropout rate due to adverse events is similar to 
that seen with placebo (Andersson, 2011). As to cardiovas-
cular safety, it has been shown that PDE5 inhibitors do not 
affect the ability of patients with coronary artery disease 
to maintain a level of exercise similar to that required for 
sexual activity and that patients do not experience signifi-
cant side effects from the use of these medications (Uckert; 
Stief, 2011). Nitrates are totally contraindicated with all 
PDE inhibitors due to unpredictable hypotension (Carson, 
2007; Andersson, 2011; Uckert, Stief, 2011).
UDENAFIL
Pharmacokinetic properties 
Udenafil (5-[2-propyloxy-5-(1-methyl-2-pyrollidi-
nylethylamidosulphonyl) phenhyl]-1-methyl-3-propyl-
1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one devel-
oped by Dong-A Pharmaceutical Company, Korea, is also 
a potent PDE5 inhibitor with a similar molecular structure 
to sildenafil citrate (Figure 1) (Kim et al., 2008; Han et 
al., 2010). Udenafil has been marketed in Korea since 
2005 under the brand name of Zydena in 100 and 200 mg 
tablet strengths for the treatment of erectile dysfunction 
(Bae et al., 2008).
At a dose of 30 mg/kg, the absorption of udenafil 
from rat intestinal tract is known to be complete (about 
99%). Thus, the absolute oral bioavailability of udenafil 
was 38.0% in rats (Shim et al., 2003). The mean plasma 
concentration–time profiles of udenafil after a single oral 
administration of udenafil 100 mg to six healthy Korean 
male volunteers and the relevant pharmacokinetic param-
eters were determined. The mean Cmax of udenafil was 
302 ± 88.5 ng/mL, Tmax 1.5 h (Kim et al., 2008). The 
half-life and AUC values of udenafil were 11.2 ± 1.62 
and 2070 ± 292 ng h/mL, respectively (Bae et al., 2008).
Methods of analysis
Only a few analytical methods using liquid chroma-
tography with ultraviolet detection and high-performance 
liquid chromatography coupled with tandem mass spec-
trometry for determination of udenafil in biological sam-
ples have been reported (Table I). No analytical method 
exists, so far, for the assay of udenafil in pharmaceutical 
formulations.
Shim et al. (2002) describe the LC method for the 
determination of udenafil in rat plasma and urine. Sample 
preparation is achieved using a liquid/liquid extraction 
procedure. It was possible to study the pharmacokinet-
ics of udenafil in rats using the detection limits obtained. 
The detection limits for udenafil in rat plasma and urine 
were 20 and 100 ng/mL, respectively. However, the lower 
limit of quantification obtained in rat plasma, 20 ng/mL, 
was considered to have insufficient sensitivity for the 
determination of udenafil in human biological samples. 
A more sensitive assay method was developed for the 
quantification of udenafil in human plasma and urine (Cho 
et al., 2003). The method was based on a modification of 
the method described by Shim et al. (2002). A single step 
liquid–liquid extraction procedure was performed and the 
lower limit for quantification was 5 ng/mL for plasma and 
10 ng/mL for urine samples. This assay was successfully 
tested in clinical phase I studies in healthy volunteers. 
Next, Kim et al. (2003a) described a LC/MS/MS 
method using liquid–liquid extraction for the determina-
tion of udenafil in human plasma. The method showed 
FIGURE 1 - Chemical structure of udenafil.
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sensitivity (2.0 ng/mL) and the suitability of the method 
was confirmed in the pharmacokinetic study of udenafil 
in man.
Kim et al. (2008) conducted the first-in-human 
clinical trial to evaluate the safety, tolerability and 
pharmacokinetic characteristics after single and mul-
tiple oral administrations in healthy male subjects. The 
determination of udenafil concentrations in plasma and 
urine were performed using high-performance liquid 
chromatography, as described by Shim et al. (2002), with 
slight modifications.
According to Bae et al. (2008) the reported meth-
ods required time-consuming and laborious extraction 
procedures after sample alkalization (Shim et al., 2002; 
Cho et al., 2003; Kim et al., 2003b), or a relatively large 
sample volume of 1 mL (Cho et al., 2003) and also long 
chromatographic run times (Shim et al., 2002; Cho et al., 
2003; Kim et al., 2003b), which lower sample throughput 
capacity and sensitivity. In order to solve these problems 
Bae et al. (2008) proposed a rapid, sensitive, simple and 
accurate method for simultaneous determination of ude-
nafil and its active metabolite in human plasma and urine 
using ultraperformance liquid chromatography coupled 
to tandem mass spectrometry (UPLC/MS/MS) with di-
rect injection after simple protein precipitation. UPLC 
separation was achieved using an Acquity™ UPLC BEH 
C18 column (50 x 2.1 mm, i.d.; particle size, 1.7 μm; 
Waters, Milford, MA, USA). The isocratic mobile phase 
consisting in acetonitrile and 0.1% formic acid (75:25, 
v/v), the flow rate 0.4 mL/min and total run time less 
than 1 min. The concentrations of udenafil and its active 
metabolite in human plasma or urine were quantified 
using a Quattro Premier™ XE tandem quadrupole mass 
spectrometer (Waters, Milford, MA, USA) equipped with 
an electrospray ionization interface used to generate posi-
tive ions [M + H]+. This method was successfully applied 
to a pharmacokinetic study of udenafil 100 mg in healthy 
Korean male volunteers.
Ku et al. (2011) described a more sensitive and 
rapid analysis of udenafil in rat plasma, using an LC-MS/
MS system, aiming to replace the previous methods. The 
authors justify their work due to the large plasma volume 
used, long retention times and because pharmacokinetic 
studies in animal model had to be conducted at high doses 
considering the low limit of quantification of the methods 
previously published (Shim et al., 2002; Cho et al., 2003; 
Kim et al., 2003b, Bae et al., 2008). The method resulted in 
a low limit of quantification (0.5 ng/mL), low plasma vol-
ume (0.1 mL) and relatively short running time (2.5 min). 
They intended this method to be used for the analysis of 
drug concentration in plasma after intravenous, intranasal 
and oral administrations in rats. 
LODENAFIL
Pharmacokinetics properties
Lodenafil carbonate, bis-(2-{4-[4-ethoxy-3-(1-
methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]
pyrimidin-5-yl)-benzenesulfonyl]piperazin-1-yl}-ethyl) 
TABLE I - Parameters described in the literature to determine udenafil using liquid chromatography
Reference Sample Column Mobile phase/flow/gradient Detector
Shim et al. (2002) rat plasma and 
urine
C18 column (150 mm x 4.6 
mm, i.d.; 5 µm particle size; 
Hichrom HPRPB, Berkshire, 
UK)
20 mM KH2PO4 (pH 4.7):acetonitrile 
(70:30, v/v for plasma and 75:25, 
v/v for urine
Samples/1.0 mL/min /isocratic
UV
Cho et al. (2003) human plasma 
and urine
C18 column (150 mm × 
4.6 mm i.d.; 5 µm particle size; 
Shiseido, Tokyo, Japan)
30% acetonitrile:70% 20mM 
potassium phosphate buffer 
(pH 4.5) /1.0 mL/min/isocratic
UV
Kim et al. 
(2003b)
human plasma luna phenylhexyl column 
(100 mm x 2 mm; i.d. 3 µm 
particle size; Phenomenex, 
Torrance, CA, USA)
acetonitrile:ammonium formate 
(5mM, pH 6.0) (60:40, v/v)/
0.2 mL/min/isocratic
MS/MS
Kim et al. (2008) plasma and 
urine
C18 column (150 x 4.6 
mm i.d.; 5 µm particle size; 
Shiseido, Tokyo, Japan)
acetonitrile:20 mM potassium phosphate 
buffer of pH 4.5 (30:70%, v/v)/
1.0 mL/min, isocratic
UV
Ku et al. (2011) rat plasma C18 column (50 mm x 2.1 
mm; i.d., 3µm particle size; 
Varian Inc., CA, USA)
acetonitrile:10 mM ammonium acetate 
(90 : 10, v/v)/0.2 mL/min/isocratic
MS/MS
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(Figure 2) has a unique chemical structure; a carbonate 
bridge unites 2 molecules of lodenafil. After ingestion 
the carbonate bridge is broken freeing each molecule of 
lodenafil for biologic effect (Glina et al., 2010; Toque et 
al., 2010; McNamara; Donatucci, 2011).
The inhibition of cGMP hydrolysis by sildenafil, 
lodenafil or lodenafil carbonate was determined at vari-
ous concentrations, and the results showed that lodenafil 
carbonate was more potent than lodenafil or sildenafil to 
inhibit PDE5 in human platelets. Lodenafil carbonate was 
completely metabolized into lodenafil by rat plasma. Incu-
bation of lodenafil carbonate with human plasma and dog 
plasma demonstrated that a small proportion of lodenafil 
carbonate was metabolized to lodenafil and to an unknown 
metabolite (Toque et al., 2008).
After oral intake of 160 mg under fasting condition, 
Cmax was 157 ng/mL, Tmax was 1.2 h, T1/2 was 2.4 h 
and AUC was 530 ng h/mL. For oral administration with 
a 600 kcal lipid meal, the parameters were: Cmax = 148 
ng/mL; Tmax = 3.1 h; T1/2 = 2.63 h; AUC = 683 ng h/mL. 
Therefore, administration with lipids delayed the absorp-
tion but increased the bioavailability (Lucio et al., 2007; 
Glina et al., 2010).
Methods of analysis
The development of lodenafil carbonate was re-
ported by Toque et al. (2008). They observed the effects of 
lodenafil carbonate on rabbit and human corpus caverno-
sum relaxation, activity of PDE5 in human platelets, sta-
bility and metabolic studies in comparison with sildenafil 
and lodenafil, as well as the pharmacological evaluation of 
lodenafil carbonate after intravenous and oral administra-
tion in male beagles.
The determination of PDE activity, stability of lode-
nafil carbonate in human, dog and rat plasma and the phar-
macokinetic parameters after a single intravenous or oral 
dose was carried out by LC-MS/MS analysis (Table II).
Codevilla et al. (2011a) developed a stability-
indicating reversed-phase liquid chromatography method 
using ultraviolet (UV) detection for the quantitative de-
termination of lodenafil carbonate in tablets. The method 
can be useful for routine quality control assay and stability 
studies.
Another study for the determination of lodenafil 
carbonate in tablets was developed by Codevilla et al. 
(2011b). As an alternative to the LC method the authors 
suggested a UV-spectrophotometric method for the 
analysis of lodenafil carbonate in pharmaceutical form. 
The UV method offers advantages over other analytical 
methods due to its rapidity, simplicity, and lower cost. 
Recently, Codevilla et al. (2012) developed and validated 
a capillary zone electrophoresis (CZE) method for deter-
mination of lodenafil carbonate in drug products. There 
are some advantages to use the CZE method, such as 
rapid analysis, small sample and reagent consumption, 
high separation efficiency (Furlanetto et al., 2001; Yang 
et al., 2010). The results obtained from the UV-spectro-
photometric method and CZE method were compared 
statistically with the LC method (Codevilla et al., 2011a) 
and the results showed no significant difference between 
these methods. 
TABLE II - Parameters described in the literature to determine lodenafil carbonate using liquid chromatography
Reference Sample Column Mobile phase/flow/gradient Detector
Toque et al., 2009 rat, dog and 
human plasma
C18 column (150 mm x 
4.6 mm i.d.; 4 μm particle 
size; Phenomenex, 
Torrance, CA, USA)
A=H2O-ammonium acetate 50 mM; 
B=CH3CN-ammonium acetate 50 mM)/
1.5 mL/min/gradient
MS/MS
Codevilla et al., 
2011a
tablets C18 column (250 mm x 
4.6 mm i.d.; 4 μm particle 
size; Phenomenex, 
Torrance, CA, USA)
Methanol:acetic acid 0.1%, pH 4.0 
(65:35, v/v)/1.0 mL/min/isocratic
UV
FIGURE 2 - Chemical structure of lodenafil carbonate.
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MIRODENAFIL 
Pharmacokinetic properties 
Mirodenafil, 5-ethyl-2-f-5-[4-(2-hydroxyethyl)
piperazine-1-sulfonyl]-2-phenylg -7-propoxypropyl-3,5-
dihydropyrrolo-[3,2-d]-pyrimidin-4-one (Figure 3), is a 
new PDE-5 inhibitor that came into the market recently 
(Choi et al., 2009; Lee et al., 2009).
Promising animal studies showed that the maximum 
concentration of mirodenafil is higher than the one of silde-
nafil in plasma and corpus cavernosum tissue (McNamara, 
Donatucci, 2011). The pharmacokinetic parameters in 
plasma and corpus cavernosum are defined after a single 
oral administration. The Cmax and AUC of mirodenafil in 
plasma were 2728 ng/mL and 5702 ng h/mL, respectively. 
The Tmax was 1.0 h and the half-life was 1.5 h. In the 
corpus cavernosum the Cmax of mirodenafil was 2812 
ng/mL, AUC 8425 ng h/mL, Tmax 1.4 h and the half-life 
1.3 h (Lee et al., 2009).
METHODS OF ANALYSIS
Two methods were published for the determination 
of mirodenafil in biological fluids. Choi et al. (2009) de-
scribe an isocratic reversed-phase liquid chromatographic 
method for simultaneous analysis of mirodenafil and its 
two main metabolites, SK3541 and SK3544, in rat plasma, 
urine, and tissue homogenates. The authors used a simple 
deproteinization procedure for sample preparation, and the 
compounds were separated on a C18 column (250 mm x 
4.6 mm, i.d.; 5 μm particle size; Shiseido, Tokyo, Japan). 
The mobile phase was constituted with 0.02 M ammonium 
acetate buffer (pH 6):acetonitrile (52:48, v/v) at a flow rate 
of 1.4 mL/min. UV detection was at 254 nm.
Lee et al. (2009) developed a study with the 
proposed method to determine sildenafil and mirode-
nafil in the plasma and corpus cavernosum tissue of 
rats using LC–MS/MS. A CapcellPak phenyl column 
(2.1mm x 150 mm, 5 μm) maintained constant at 40 °C 
was used for the separation. The mobile phase consisted 
of 90% acetonitrile in 5 mM ammonium formate (pH 6.0). 
A gradient program was used for the LC separation with a 
flow rate of 0.2 mL/min.
AVANAFIL
Pharmacokinetic properties 
Avanafi l  (4-[(3-chloro-4-methoxybenzyl)
amino]-2-[2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-
pyrimidinylmethyl)-5-pyrimidinecarboxamide;(S)-
2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-
methoxybenzylamino)-5-[(2-pyrimidinylmethyl)carbam-
oyl]pyrimidine) (Figure 4) is a selective PDE5 inhibitor 
developed by Mitsubishi Tanabe Pharma Corporation 
(Osaka, Japan) (Jung et al., 2010; Alwaal et al., 2011).
VIVUS Inc. is in the process of developing avanafil, 
a fast-acting, highly selective PDE5i, as an oral medica-
tion for the treatment of ED. Avanafil was generally well 
tolerated and had linear pharmacokinetic properties at 
daily doses of 50 to 200 mg over 7 days in healthy Ko-
rean male volunteers (Uckert, Stief, 2011). Avanafil oral 
tablets will be available in 50, 100, and 200 mg (Traynor, 
2012). A mean Tmax was reached at 0.33 to 0.52 h after 
oral dosing and then declined with a mean apparent T1/2 
of 5.36 to 10.66 h. AUC and Cmax in a single-dose were 
2217 ng h/mL and 1206 ng/mL, respectively (Jung et al., 
2010). A randomized, double-blind, placebo-controlled 
Phase III study evaluating two doses of avanafil (100 and 
200 mg) in 390 men with both diabetes and ED, showed 
satisfactory results. FDA requires Vivus Inc. to perform 
two post-marketing clinical trials, in order to observe pos-
sible adverse events associated with the use of avanafil 
(Traynor, 2012).
Methods of analysis
Recently avanafil has gone through the phase I, II 
and III clinical trials and this could be the reason for few 
publications about methods of analysis of this drug. Jung 
FIGURE 3 - Chemical structure of mirodenafil.
FIGURE 4. Chemical structure of avanafil.
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et al. (2010) developed a study to meet Korean regulatory 
requirements for the marketing of avanafil. They observed 
the tolerability and pharmacokinetic properties of single 
and multiple oral doses of avanafil in healthy Korean male 
volunteers. The plasma concentrations of avanafil were 
measured by a sensitive and selective method using on-
line solid-phase extraction (SPE) coupled to LC-MS/MS. 
Chromatographic separation was conducted using a C18 
column (50 mm x 2.0 i.d.; 3 μm particle size; Shiseido, 
Tokyo, Japan). The mobile phase consisted of a mixture 
of 10 mM ammonium formate (pH 2.5) and acetonitrile 
(65:35, v/v), with a flow rate of 0.3 mL/min.
CONCLUSION
Phosphodiesterase type 5 inhibitors are currently the 
therapeutic option of choice for erectile dysfunction. This 
review highlighted the mechanism of action of the PDE5i, 
some adverse effects, pharmacokinetic and analytical 
methods for the determination of four phosphodiesterase 
type 5 inhibitors in different matrices. As shown, there 
are few reports for the new PDE5i, udenafil, lodenafil 
carbonate, mirodenafil and avanafil, especially concerning 
the determinations of these drugs. Hence, in this paper we 
compiled applied methods, such as LC-UV, LC-MS and 
LC-MS/MS, in biological matrices and pharmaceutical 
formulations. For each of the compiled methods positive 
and negative features can be considered because some of 
them are simpler and of lower cost, but result in not so 
much informations, whereas others result in many infor-
mations about the drug, but need especial instrumentation 
and are very expensive. With the application of these 
methodologies quality control routine will be possible, 
assuring drug safety. A major feature of this paper is the 
compilation of information about udenafil, lodenafil car-
bonate, mirodenafil and avanafil in the same paper.
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